Prognosticating 2-Year Survival Rate of Breast Cancer Patients Through Plasma miRNA-21 and Other Associating Factors

Romadhon, Pradana Zaky; Ashariati, Ami; Bintoro, Siprianus Ugroseno Yudho; Diansyah, Muhammad Noor; Amrita, Putu Niken Ayu; Savitri, Merlyna; Suryantoro, Satriyo Dwi; Prahasanti, Kartika; Wijaya, Andi Yasmin; Hendrata, Winona May; Windradi, Choirina; Mahdi, Bagus Aulia; Widiyastuti, Krisnina Nurul; Agustin, Esthiningrum Dewi

doi:10.2147/ijgm.s361934

Cited by 1 publication

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies by Romadhon et al, (2021) have examined the relationship between plasma levels of miRNA-21 and overall survival rate as a prognostic factor in breast cancer at Airlangga University Hospital. However, based on a search of the current library, research on the analysis of chemotherapy regimens for survival in breast cancer patients housed in Airlangga University Hospital has not been conducted.…”

Section: Introductionmentioning

confidence: 99%

“…However, based on a search of the current library, research on the analysis of chemotherapy regimens for survival in breast cancer patients housed in Airlangga University Hospital has not been conducted. Survival analysis includes metrics for assessing disease mortality and morbidity, survival rates related to risk factors and success of cancer treatment therapies (Dwidayati, 2012;Romadhon et al, 2021).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Analysis of Chemotherapy Regimens on Survival Rate of Breast Cancer Patients

Yulistiani,

Utomo,

Romadhon

et al. 2024

Preprint

Self Cite

View full text Add to dashboard Cite

Breast cancer in Indonesia is among the first with the highest number of new cancer cases with the second mortality in cancer after lung cancer in 2020. Anthracycline-taxane based regimens and taxane-based regimens are often breast cancer chemotherapy modalities that can support increased patient survival. Side effects occur more frequently in combination regimens. The selection of the right regimen is expected to support the improvement of patient survival. This study aims to analyze the survival rate of chemotherapy regimen groups and hazard ratio factors that are thought to affect survival in breast cancer patients. This study used an observational and retrospective cohort method. The statistical analyzes used in this study include Kaplan-Meier analysis to measure survival rates, Log-rank test to observe the differences between regimen groups and Cox proportional hazards regression to analyze factors that influence survival. Patients who were included in the inclusion and exclusion criteria were 71 patients, consisting of 47 patients who received anthracycline-taxane based combination and 24 patients who received taxane-based chemotherapy. The percentage of one-year and two-year survival in the anthracycline-taxane based combination was 93.6% and taxane-based 83.3% (p>0.05). Multivariate analysis showed that stage increased risk 9 times based on hazard ratio values obtained from cox regression tests (HR 9.60; 95% CI 1.60-57.54; p<0.05). Another significant factor in the multivariate analysis was that delaying chemotherapy increased the risk of survival 5 times (HR 5,58; CI 95% 1.12-27.85 ; p<0.05). Based on research, it can be concluded that anthracycline-taxane based and taxane based combination regimens can be used as a treatment modality for breast cancer patients in both early and advanced stages.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%